Genentech said FDA accepted the company’s supplemental Biologics License Application and granted Priority Review for Tecentriq (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin chemotherapy, and are either previously untreated or have disease progression at least 12 months after receiving chemotherapy before surgery or after surgery.
Grants are flowing out of NCI again to beat the fiscal-year end deadline and some cancer researchers are starting to feel cautiously optimistic about the future.
